DE60212825T2 - Selbsterhaltender lactococcus stamm - Google Patents
Selbsterhaltender lactococcus stamm Download PDFInfo
- Publication number
- DE60212825T2 DE60212825T2 DE60212825T DE60212825T DE60212825T2 DE 60212825 T2 DE60212825 T2 DE 60212825T2 DE 60212825 T DE60212825 T DE 60212825T DE 60212825 T DE60212825 T DE 60212825T DE 60212825 T2 DE60212825 T2 DE 60212825T2
- Authority
- DE
- Germany
- Prior art keywords
- gene
- lactococcus
- strain
- thya
- lactis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000194036 Lactococcus Species 0.000 title abstract description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 47
- 241000178948 Lactococcus sp. Species 0.000 claims description 15
- 230000001225 therapeutic effect Effects 0.000 claims description 15
- 108010022394 Threonine synthase Proteins 0.000 claims description 12
- 230000000069 prophylactic effect Effects 0.000 claims description 12
- 108090000174 Interleukin-10 Proteins 0.000 claims description 7
- 102000003814 Interleukin-10 Human genes 0.000 claims description 6
- 229940076144 interleukin-10 Drugs 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000035899 viability Effects 0.000 abstract description 9
- 150000001875 compounds Chemical class 0.000 abstract description 8
- 101150072314 thyA gene Proteins 0.000 description 38
- 101100153154 Escherichia phage T5 thy gene Proteins 0.000 description 34
- 101100427060 Bacillus spizizenii (strain ATCC 23059 / NRRL B-14472 / W23) thyA1 gene Proteins 0.000 description 30
- 101100313751 Rickettsia conorii (strain ATCC VR-613 / Malish 7) thyX gene Proteins 0.000 description 30
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 28
- 101001033233 Homo sapiens Interleukin-10 Proteins 0.000 description 27
- 241000194035 Lactococcus lactis Species 0.000 description 27
- 102000052620 human IL10 Human genes 0.000 description 26
- 239000013612 plasmid Substances 0.000 description 21
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 14
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 14
- 229940104230 thymidine Drugs 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 12
- 235000014897 Streptococcus lactis Nutrition 0.000 description 12
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 7
- 239000012228 culture supernatant Substances 0.000 description 7
- 230000006801 homologous recombination Effects 0.000 description 7
- 238000002744 homologous recombination Methods 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 108700005090 Lethal Genes Proteins 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000001332 colony forming effect Effects 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229940113082 thymine Drugs 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 102000005497 Thymidylate Synthase Human genes 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 101800000135 N-terminal protein Proteins 0.000 description 2
- 101800001452 P1 proteinase Proteins 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000009655 industrial fermentation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000013615 primer Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 210000001938 protoplast Anatomy 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108090000363 Bacterial Luciferases Proteins 0.000 description 1
- 101100189378 Caenorhabditis elegans pat-3 gene Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 206010061765 Chromosomal mutation Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 241000701832 Enterobacteria phage T3 Species 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 101100487689 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) yafQ gene Proteins 0.000 description 1
- 101100340711 Homo sapiens IL10 gene Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 241000194041 Lactococcus lactis subsp. lactis Species 0.000 description 1
- 101900156096 Lactococcus lactis subsp. lactis Thymidylate synthase Proteins 0.000 description 1
- 101100468239 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) relE3 gene Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 102100024819 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 235000014969 Streptococcus diacetilactis Nutrition 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 101150115929 Usp45 gene Proteins 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000010868 animal carcass Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000031261 interleukin-10 production Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 101150081840 relE gene Proteins 0.000 description 1
- 101150044854 repA gene Proteins 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y201/00—Transferases transferring one-carbon groups (2.1)
- C12Y201/01—Methyltransferases (2.1.1)
- C12Y201/01045—Thymidylate synthase (2.1.1.45)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01201631 | 2001-05-03 | ||
| EP01201631 | 2001-05-03 | ||
| EP01204785 | 2001-12-07 | ||
| EP01204785 | 2001-12-07 | ||
| PCT/EP2002/004942 WO2002090551A2 (en) | 2001-05-03 | 2002-05-03 | Self-containing lactococcus strain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60212825D1 DE60212825D1 (de) | 2006-08-10 |
| DE60212825T2 true DE60212825T2 (de) | 2007-01-11 |
Family
ID=26076897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60212825T Expired - Lifetime DE60212825T2 (de) | 2001-05-03 | 2002-05-03 | Selbsterhaltender lactococcus stamm |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1383897B1 (enExample) |
| JP (2) | JP4347575B2 (enExample) |
| AT (1) | ATE331789T1 (enExample) |
| AU (1) | AU2002314040B2 (enExample) |
| CA (1) | CA2446776C (enExample) |
| DE (1) | DE60212825T2 (enExample) |
| DK (1) | DK1383897T3 (enExample) |
| ES (1) | ES2266515T3 (enExample) |
| WO (1) | WO2002090551A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7780961B2 (en) | 2001-05-03 | 2010-08-24 | Actogenix N.V. | Self-containing Lactococcus strain |
| EP1513545B1 (en) | 2002-06-19 | 2008-03-19 | Actogenix N.V. | Methods and means to promote gut absorption |
| WO2004056850A2 (en) * | 2002-12-19 | 2004-07-08 | Vib Vzw | Mutant proteins showing increased secretion |
| JP4589618B2 (ja) | 2003-11-28 | 2010-12-01 | 独立行政法人農業生物資源研究所 | 免疫調節性機能を誘導する乳酸菌類とその成分 |
| WO2006018446A2 (en) | 2004-08-20 | 2006-02-23 | Actogenix Nv | Method to improve lactococcus preservation |
| ES2405552T3 (es) | 2005-11-29 | 2013-05-31 | Actogenix N.V. | Inducción de tolerancia mucosa a antiantígenos de células beta de islotes pancreáticos |
| CA2672229A1 (en) * | 2006-12-14 | 2008-06-19 | Actogenix N.V. | Delivery of binding molecules to induce immunomodulation |
| EP3124614B1 (en) | 2007-01-12 | 2022-06-08 | Intrexon Actobiotics NV | Lactococcus promoters and uses thereof |
| EP2774621B1 (en) | 2007-01-25 | 2018-01-24 | Intrexon Actobiotics NV | Treatment of immune disease by mucosal delivery of antigens |
| EP2344626B1 (en) * | 2008-09-29 | 2017-03-29 | Intrexon Actobiotics NV | Reduced colonization of microbes at the mucosa |
| US9920324B2 (en) | 2011-06-01 | 2018-03-20 | Intrexon Actobiotics Nv | Polycistronic expression system for bacteria |
| EP2758512B1 (en) | 2011-09-23 | 2018-05-09 | Intrexon Actobiotics NV | Modified gram positive bacteria and uses thereof |
| BR112014006883A8 (pt) | 2011-09-23 | 2018-06-26 | Actogenix Nv | bactéria gram-positiva não patogênica carecendo de atividade do componente llc do sistema pts celobiose específico (ptcc), medicamento, aditivo alimentar, composição probiótica, ou cultura iniciadora, produto alimentar e métodos |
| US9688967B2 (en) | 2014-12-05 | 2017-06-27 | Synlogic, Inc. | Bacteria engineered to treat diseases associated with hyperammonemia |
| US10610546B2 (en) | 2015-05-13 | 2020-04-07 | Synlogic Operating Company Inc. | Bacteria engineered to reduce hyperphenylalaninemia |
| US20160206666A1 (en) | 2014-12-22 | 2016-07-21 | Synlogic, Inc. | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier |
| JP7095993B2 (ja) * | 2015-03-02 | 2022-07-05 | シンロジック オペレーティング カンパニー インコーポレイテッド | 消化管炎症低下および／または消化管粘膜バリア強化の利益を享受する疾患処置のために操作された細菌 |
| CN106148254B (zh) * | 2015-03-26 | 2019-11-12 | 南京华贞生物医药科技有限公司 | 一种用于减肥降脂的转化体及其构建方法与应用 |
| US11685925B2 (en) | 2015-10-30 | 2023-06-27 | Synlogic Operating Company, Inc. | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier |
| EP3377518B1 (en) | 2015-11-16 | 2022-04-13 | Synlogic Operating Company, Inc. | Bacteria engineered to reduce hyperphenylalaninemia |
| EP3402499B1 (en) | 2016-01-14 | 2021-07-21 | Intrexon Actobiotics NV | Compositions and methods for the treatment of type 1 diabetes |
| CN109843320A (zh) | 2016-09-02 | 2019-06-04 | 英特瑞克斯顿阿克图比奥帝克斯有限公司 | 稳定表达il-10和胰岛素的遗传修饰的细菌 |
| RU2762940C2 (ru) | 2016-09-13 | 2021-12-24 | Интрексон Актобиотикс Н.В. | Мукоадгезивный микроорганизм |
| WO2020075171A1 (en) | 2018-10-11 | 2020-04-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Bacteria expressing single chain antibodies against toll-like receptors |
| CN114761028A (zh) | 2019-09-27 | 2022-07-15 | 英特瑞克斯顿阿克图比奥帝克斯有限公司 | 乳糜泻的治疗 |
| BR112022018571A2 (pt) | 2020-03-20 | 2022-11-01 | Synlogic Operating Co Inc | Microrganismos manipulados para reduzir a hiperfenilalaninemia |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4231764A1 (de) * | 1992-09-23 | 1994-03-24 | Inst Pflanzengenetik & Kultur | Verfahren zur chromosomalen Integration eines Produkt-Gens |
-
2002
- 2002-05-03 JP JP2002587611A patent/JP4347575B2/ja not_active Expired - Fee Related
- 2002-05-03 CA CA2446776A patent/CA2446776C/en not_active Expired - Fee Related
- 2002-05-03 EP EP02740565A patent/EP1383897B1/en not_active Expired - Lifetime
- 2002-05-03 DE DE60212825T patent/DE60212825T2/de not_active Expired - Lifetime
- 2002-05-03 DK DK02740565T patent/DK1383897T3/da active
- 2002-05-03 ES ES02740565T patent/ES2266515T3/es not_active Expired - Lifetime
- 2002-05-03 WO PCT/EP2002/004942 patent/WO2002090551A2/en not_active Ceased
- 2002-05-03 AT AT02740565T patent/ATE331789T1/de active
- 2002-05-03 AU AU2002314040A patent/AU2002314040B2/en not_active Ceased
-
2008
- 2008-10-07 JP JP2008260591A patent/JP2009060913A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002090551A3 (en) | 2003-03-27 |
| JP2004533246A (ja) | 2004-11-04 |
| ES2266515T3 (es) | 2007-03-01 |
| EP1383897A2 (en) | 2004-01-28 |
| EP1383897B1 (en) | 2006-06-28 |
| DE60212825D1 (de) | 2006-08-10 |
| JP4347575B2 (ja) | 2009-10-21 |
| WO2002090551A2 (en) | 2002-11-14 |
| DK1383897T3 (da) | 2006-10-30 |
| AU2002314040B2 (en) | 2007-06-28 |
| CA2446776C (en) | 2011-07-12 |
| JP2009060913A (ja) | 2009-03-26 |
| CA2446776A1 (en) | 2002-11-14 |
| ATE331789T1 (de) | 2006-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60212825T2 (de) | Selbsterhaltender lactococcus stamm | |
| AU2002314040A1 (en) | Self-containing lactococcus strain | |
| US20050101005A1 (en) | Self-containing Lactococcus strain | |
| US20050276788A1 (en) | Self-containing lactobacillus strain | |
| DE3308030C2 (de) | Tierische Interferone | |
| DD216044A5 (de) | Verfahren zur herstellung eines rekombinierenden dna-klonierungsvektors | |
| DE69611794T2 (de) | Stabilisierung von plasmiden | |
| DE60319083T2 (de) | Pharmazeutische verbindung und methoden zur behandlung von menschlichen karzinomen mittels arginin-entzug | |
| EP0342633B1 (de) | Bacillus thuringiensis Transformation | |
| DE69434196T3 (de) | Einen eingefügten Promotor enthaltendes rekombinantes Milchsäure Bakterium | |
| DE60023501T2 (de) | Einstufiger allel-austausch in mykobakterium mittels konditionell transduzierendem phagen | |
| DE60204317T2 (de) | Methode zur plasmidstabilisierung durch in vivo deletion der antibiotikaresistenz und selektion mit einem essentiellen gen | |
| DE68929370T2 (de) | Verfahren zur Selektion und zur stabilen Einschleusung rekombinanter DNA in Milchsäurebakterien | |
| EP0775203B1 (de) | Gentherapeutisches verfahren unter verwendung von dna-vektoren ohne selektionsmarker-gen | |
| KR20070026575A (ko) | 자족형 락토바실러스 균주 | |
| EP0501921B1 (de) | Verfahren zur genetischen Manipulation von Myxobakterien | |
| EP0751999A1 (de) | Gentherapeutisches verfahren unter verwendung von antibiotikaresistenzgenfreien dna-vektoren | |
| EP1023453B1 (de) | Tgc-verfahren zur induktion einer zielgerichteten, somatischen transgenität | |
| DE69416673T2 (de) | Kontakt-vermitteltes hämolysin regulator | |
| DE69105188T2 (de) | Asporogener Stamm von Bacillus substilis und seine Verwendung als Wirt in der Herstellung von heterologen Produkten. | |
| DE4231764A1 (de) | Verfahren zur chromosomalen Integration eines Produkt-Gens | |
| DE69106498T2 (de) | Stamm ral-4, nützlich zur herstellung kleiner proteine und peptide. | |
| WO2004113575A1 (de) | Plasmidfreier klon des e. coli-stammes dsm 6601 | |
| WO2002095011A2 (de) | Inaktivierung von genen des mep-wegs | |
| DE102022119024A1 (de) | Neuartige genetische Werkzeuge |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: ACTOGENIX NV, ZWIJNAARDE, BE |
|
| 8328 | Change in the person/name/address of the agent |
Representative=s name: HUBER & SCHUESSLER, 81825 MUENCHEN |